August 27, 2020 07:00 AM EDTUpdated 07:26 AM

Triumvira snags $55M Series A to guide TAC technology to the clinic

Nicole DeFeudis

Editor

Triumvira Immunologics wants to bring its T-cell antigen coupler (TAC) technology to the clinic early next year, and it plans on riding a $55 million Series A to get there.

The Austin, TX-based biotech announced the completion of its financing round on Thursday. And now president and CEO Paul Lammers says it’s “all hands on deck” to submit an IND for the company’s HER2-directed TAC for solid tumor patients. Lammers hopes the TAC will be ready for human testing in late Q1 of 2021.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Triumvira snags $55M Series A to guide TAC technology to the clinic

Nicole DeFeudis

Editor

To read Endpoints News become a free subscriber

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Tri­umvi­ra snags $55M Se­ries A to guide TAC tech­nol­o­gy to the clin­ic

Nicole DeFeudis

Editor

To read Endpoints News become a free subscriber

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Triumvira snags $55M Series A to guide TAC technology to the clinic

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape